Regeneron Pharmaceuticals REGN

Reference table

1. The June quarter, decomposed — where the growth actually came from

Filed, from the 10-Q revenue table ($M):

The single most important arithmetic in this dive: the Sanofi line rose $730.7 million and total revenue rose $615.1 million. Everything else, in aggregate, went BACKWARDS by $115.6 million.

The Sanofi collaboration is the Dupixent profit share. From the 10-Q: "The Company is party to a global collaboration with Sanofi... which currently consists of Dupixent (dupilumab), Kevzara (sarilumab), and itepekimab... The parties equally share profits from sales within the United States, and share profits outside the United States on a sliding scale based on sales starting at 65% (Sanofi)/35% (Regeneron)." At $2,174.3 million it is 50.7% of Regeneron's total revenue, and it grew 50.6%.

The ophthalmology franchise is in structural transition and the transition is not yet net-neutral. The 10-Q states: "EYLEA net product sales have been, and are likely to continue to be, negatively impacted by increased competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD. The magnitude and duration of such impact is presently unknown." US EYLEA fell $342.1 million; EYLEA HD gained $203.1 million; the net is minus $139.0 million, a 12.1% decline in the combined franchise.

And GAAP earnings fell.

Revenue up 16.7%, GAAP earnings down 6.8%, adjusted earnings 40.6% above consensus. The gap between those three statements is the most important thing to understand about this quarter: the adjusted beat is real, the GAAP decline is also real, and the reconciliation runs through research and development at 41.6% of revenue plus the Limerick manufacturing interruption management has disclosed.

The beat pattern is persistent and enormous: +52.9% (August 2025), +22.6% (October 2025), +6.5% (January 2026), +6.3% (April 2026) and +40.6% (July 2026). Consensus does not model this company well, which is a statement about the estimate base every valuation here depends on.

2. Balance sheet, cash generation and capital return

From bal_a at 2025-12-31 and the 10-Q cash flow for the half ($M):

Approximately $6.6 billion of net cash — 8.4% of market capitalisation — and no goodwill at all. The payload's netDebt of −$412.2M is computed as $2,705.9M of "total debt" (which includes $720M of capital lease obligations) less cash only, ignoring the $5,487.1M of short-term investments entirely. That is the documented short-term-investment omission, and it understates the net-cash position by roughly $7.0 billion.

Cash flow, first half, filed:

Operating cash flow fell 13.6% in the first half while revenue rose 17.8% — the same divergence visible in GAAP earnings, and it is not explained in the extracted text. Capital returns of $2,158.3 million in the half exceeded free cash flow of $1,421.1 million by 52%, funded from the balance sheet.

Fiscal 2025, per the payload: repurchases $3,970.7 million and dividends $370.3 million — $4,341.0 million, or 5.54% of market capitalisation. Management disclosed in April 2026 "a new $3.0 billion share repurchase program with no time limit, plus a $0.94 per share dividend" (half-weighted).

3. Valuation — priced in or room?

At $760.49 (market capitalisation $78.35B; 106.8 million weighted-average diluted shares in the June quarter):

The FY2027 estimate range of $32.09 to $69.15 — a 115% spread on ten analysts — is more than three times the widest dispersion anywhere else in this batch and it is the honest centre of this dive. It is not analyst laziness; it is the correct response to an ophthalmology franchise in structural decline, a partnered franchise supplying half of revenue with a 2031 expiry, and roughly fifty clinical candidates whose outcomes are binary. Note also that the FY2027 EPS estimate carries only 10 analysts against 19 on revenue — the same signature seen elsewhere in this batch when a cost or margin path is genuinely unknown.

est.ebitdaAvg and est.ebitAvg are rejected. In every year from 2023 to 2030 ebitdaAvg is exactly 43.4322% of revenueAvg and ebitAvg exactly 40.4351% — the fixed-ratio fabrication signature, holding across a period in which the company's own operating margin moved from 28.1% to 25.6%. The implied 40.4% EBIT margin is roughly fifteen points above the actual. All forward valuation uses epsAvg only.

Enterprise value is rejected as printed and rebuilt. enterpriseValueTTM reads $78,347,200,310.8 — market capitalisation less $469, in dollars — because the balance-sheet input carrying net debt of −$412.2 million was read as −412.2 (Section 6). The correct enterprise value, using cash plus short-term investments, is approximately $78,347M − $6,619M = $71,728M, and every enterprise-value multiple in this dive uses that figure. netDebtToEBITDATTM of −8.3 × 10⁻⁸ is void.

3a. What today's price assumes (the inversion)

At $760.49 — 14.4x the 2026 consensus and 13.0x 2027, or 11.9x 2027 ex-cash — the price embeds roughly:

• Adjusted EPS of $52.65 in 2026 and $58.64 in 2027. (Consensus; 16 and 10 analysts.) The first half delivered $23.76, so 2026 needs $28.89 in the second half against a September consensus of $15.60.
• The Sanofi collaboration keeps compounding at a high rate. (Our derivation from the filed revenue table.) It is 50.7% of revenue and grew 50.6%. This is the most fragile assumption in the price, not because Dupixent is at risk today but because a company whose entire growth is one partnered line has no second engine if it decelerates — and total net product sales grew 0.7% in the June quarter.
• EYLEA HD substitution eventually outruns EYLEA erosion. (Filing-derived.) US EYLEA fell 45.4% and EYLEA HD rose 51.7%, netting to a 12.1% decline in the combined franchise. The company itself says the magnitude and duration of the biosimilar impact "is presently unknown."
• The 2031 Dupixent cliff is either later, smaller, or offset by the pipeline. (Knowledge base sizes it at roughly $25bn.) At 13.0x the 2027 consensus the market is not obviously paying for a replacement, which is the bull's strongest point and the bear's too.
• The buyback continues near $4 billion a year. (Filed; $1,963.7M in the half.) At 5.5% of market capitalisation it is a large part of the expected return and it exceeded free cash flow by 52% in the first half.

3b. The return bridge (why the multiple moves)

Expected return over the next twelve months decomposes as adjusted EPS growth (+11.4%, from FY2026E $52.645 to FY2027E $58.637) + multiple drift + shareholder yield (+5.54%).

Our base assumes the multiple EXPANDS modestly, from today's 13.0x on the 2027 year to 13.5x, and the mechanism is not a re-rating of biotechnology — it is the narrowing of the estimate range itself. A 115% dispersion is a discount, and it compresses as the EYLEA transition resolves and the pipeline reports. At an unchanged 13.0x, fair value on the 2027 consensus is $761 — spot to fifty cents — and the twelve-month return is 11.4% of earnings growth plus 5.5% of shareholder yield, roughly 17%. That floor case is genuinely attractive and it is why the verdict is Hold rather than Avoid.

Sensitivity: on the FY2027E consensus mean of $58.637, 9.5x = $557, 11x = $645, 13.0x = $761 (spot), 13.5x = $792, 17x = $997.

3c. Variant perception (where we differ, what would surprise)

• We are 3.6% below the street and our disagreement is about dispersion, not level. Our $790 against consensus $819.59. Where we depart from the way this quarter has been reported is on composition: the 40.6% beat is being read as an earnings inflection, and the same filing shows GAAP earnings falling 6.8% and total net product sales growing 0.7%. Watchable number: total net product sales in the 2026-10-28 print, against $1,642.4 million and 0.7% growth.
• We think the EYLEA transition is the near-term swing factor and it is under-discussed relative to the pipeline. US EYLEA fell $342.1 million in one quarter — 8.0% of total revenue — and the company says the magnitude and duration are unknown. A stabilisation would be a genuine positive surprise; an acceleration would take the combined franchise decline past 20%.
• We take the 2031 Dupixent cliff seriously because the knowledge base's independent voice does and because it is arithmetically large. Roughly $25 billion of Dupixent sales, of which Regeneron shares half in the US and 35-45% outside it. The store also carries a specific competitive threat at conviction 65 — an oral STAT6 degrader with 90% degradation in healthy volunteers described as a "potential oral Dupixent competitor" — which would arrive well before 2031.
• We differ from the vendor data more completely than on any other name in this batch except the one that spun off half itself (Section 6): every balance-sheet-derived ratio is wrong by a factor of one million, producing a price-to-book ratio of 2,479,728x, a return on assets of 10,373,113% and a book value per share of $0.0003. The error is single-cause and repairable, and the repaired figures are sensible — but any screen using this file is ranking Regeneron on numbers that are not numbers.
• Positive surprise: garetosmab approval in August 2026, this month; total net product sales returning to growth; the EYLEA decline decelerating; a cemdisiran approval in the fourth quarter; or an upward revision to the 2027 consensus after a 40.6% beat.
• Negative surprise: US EYLEA falling below $350 million a quarter; the Sanofi line decelerating below 20%; a further complete response letter or manufacturing interruption; oral Dupixent-competitor data; or any dilution of the government pricing agreement management describes.

Synthos fair values

All three anchors are multiples of the FY2027 consensus adjusted EPS distribution — mean $58.63671, low $32.08784, high $69.15289, 10 analysts — and the reader should hold the 115% spread in mind throughout: this is the least reliable estimate base in this batch. Cross-checked against the FY2026 row (16 analysts, 35% spread) and against net cash of approximately $6.6 billion.

• Bear ~$560 — 9.55x the FY2027 consensus MEAN, or 12.2x the FY2026E low of $45.98. (The FY2027 low of $32.09 is treated as an outlier and is not used as an anchor; at 13x it would give $417, which we regard as a tail rather than a bear case.) Cross-check: 2.6% above the 52-week low of $545.94. The scenario: EYLEA erosion accelerates past EYLEA HD substitution, the Sanofi line decelerates, a pipeline readout disappoints, and the market prices the 2031 cliff early. −26.4%.
• Base ~$790 — 13.5x the FY2027 consensus MEAN of $58.637, and 12.3x ex-net-cash. Cross-check: 15.0x FY2026E; 12.0x FY2028E; approximately 2.6x repaired book value. The scenario: the ophthalmology transition stabilises, the Sanofi line keeps compounding, the buyback runs near $4 billion a year, the pipeline delivers at least one approval, and the estimate dispersion narrows modestly. +3.9%.
• Bull ~$1,000 — 14.5x the FY2027 consensus HIGH of $69.153, or 17.1x the mean. Cross-check: 15.1x FY2028E; 23.1% above the 52-week high; 2.9% below the street's high target of $1,030. The scenario: garetosmab and cemdisiran approve, fianlimab reads out positively in melanoma, EYLEA HD conversion turns the ophthalmology franchise back to growth, and the market begins paying for a pipeline that replaces Dupixent rather than discounting one that does not. +31.5%.

Base is 3.9% above spot; asymmetry roughly 1.19:1 (26.4% down, 31.5% up), before a shareholder yield of 5.54%. The expected value is mildly positive and the distribution is extremely wide. That combination — decent expected value, poor confidence, and the most overbought technical reading in the batch — is what Hold is for.

4. Knowledge base — twenty-four matches, ten of them management, four of them a documented contamination class

Raw hits: 26. Exact case-sensitive entity matches: 24. Independent name-level claims used: 4. Management-voice claims excluded from the pool: 10. Stale competitor claims excluded on content: 4. Sanofi-only or unrelated: 6.

The sweep ran entity terms REGN, Regeneron, Dupixent, Eylea, Libtayo and Sanofi, plus free text, across all 52,021 distilled claims.

The independent lane — biotech_hangout, and it contains the bear case

> 2025-09-11 · BEARISH · conviction 65 · thesis · entities: Sanofi, Regeneron · channel: biotech_hangout · no named speaker

> "Sanofi's amlitelimab hit its endpoint but trails Dupixent on efficacy; won't offset Dupixent's ~$25B 2031 patent loss, raising a new bear case."

> 2025-10-31 · BEARISH · conviction 70 · fact · entities: Catalent, Scholar Rock, Regeneron · channel: biotech_hangout

> "Catalent's Indiana plant got an FDA Official Action Indicated classification; Scholar Rock and Regeneron received CRLs — a broad manufacturing headwind for the sector."

> 2025-08-21 · neutral · conviction 45 · fact · entities: Regeneron · channel: biotech_hangout

> "Additive effect of activin on top of myostatin for lean-mass preservation is consistent with earlier Regeneron muscle data."

> 2025-10-22 · neutral · conviction 50 · fact · entities: Regeneron · channel: biotech_hangout

> "Regeneron/decibel DB-OTO gene therapy for hereditary deafness may have made the CNPV list partly due to a very low or free price point — pay-to-play concern."

And one text-only claim that is directly competitive and should not be buried:

> 2025-08-21 · bullish · conviction 65 · entities: Kymera Therapeutics · channel: biotech_hangout

> "Kymera's oral STAT6 degrader shows 90% degradation, clean safety, strong TH2 biomarker (TARC/eotaxin-3) drops in healthy volunteers — potential oral Dupixent competitor."

The 2031 patent claim is the central bear case for this company and it is well-formed: it names the mechanism, sizes the loss and identifies the intended replacement as inadequate. The complete-response-letter claim corroborates the company's own disclosure of a Limerick production interruption depressing gross margin. The Kymera claim is a specific, dated competitive threat to the exact line supplying 50.7% of revenue. Together these are a genuinely useful independent lane and they are net negative.

The management lane — ten claims, excluded from the conviction pool, quoted at half weight

Ten of the twenty-four entity matches come from REGN_mgmt at skill 0.5, all dated 2026-04-29 — a single earnings communication distilled into ten claims. Per house rule they are excluded from the conviction pool and quoted at half weight. Their factual content is nonetheless the best forward calendar available for this company and it appears nowhere in the vendor payload:

• "Board authorized a new $3.0 billion share repurchase program with no time limit, plus a $0.94 per share dividend." (conviction 70)
• "U.S. government agreement exempts Regeneron from future pricing mandates and grants three years of tariff relief in exchange for MFN pricing." (conviction 60) — if accurate, this removes the largest regulatory overhang in US biopharmaceuticals for this issuer, and it is a management characterisation of an agreement whose text is not in this archive.
• "Garetosmab FOP BLA under FDA priority review with target action date in August 2026." (conviction 55) — this month.
• "Cemdisiran myasthenia gravis NDA acceptance anticipated Q2 2026, with FDA decision expected in Q4 2026." (conviction 55)
• "GAAP gross margin will remain negatively impacted by Limerick production interruption until output returns to normal, expected by end of Q2 2026." (conviction 70, BEARISH)
• "On track to report Phase 3 first-line metastatic melanoma results for fianlimab plus cemiplimab in Q2 2026."; "Fianlimab adjuvant melanoma second interim and final analyses anticipated in second half of 2026; company remains blinded."
• "Plans to initiate additional Phase 3 studies for Factor XI antibodies REGN7508 and REGN9933 later this year."
• "Advancing nearly 50 clinical candidates while expanding R&D and manufacturing footprint."
• "Anticipates FDA regulatory decision on one or both EYLEA HD pre-filled-syringe filling applications during Q2 2026."

The contamination check — the warning fired, and the answer is nuanced

This dive was directed to check the documented eli_lilly_ceo cross-contamination class, in which that channel carries other companies' claims under the wrong label. FOUR claims on that channel carry Regeneron or REGN in their entity lists:

> 2021-06-19 — "Lilly chose speed/scale over perfection on COVID antibodies (~80% of US antibody-treated patients); Regeneron's combination looks more variant-resistant."

> 2021-03-04 — "Existing antibodies including Regeneron's cocktail show reduced potency against B.1.351 South Africa strain."

> 2020-12-08 — "Roche–Regeneron partnership leverages Roche's large monoclonal antibody manufacturing to scale the antibody cocktail."

> 2020-09-04 — "Roche-Regeneron neutralizing antibody cocktail given early to high-risk or exposed patients could treat or prophylactically protect."

On inspection these are NOT misattributed. They are genuine comparative statements about Regeneron's products, made by a competitor's chief executive, and the entity tagging is correct. They are excluded for a different reason: all four date from 2020-2021, all four concern the COVID-19 antibody cocktail, and that product line no longer contributes materially to this company. They are stale competitor commentary on a discontinued franchise, and the distinction between "wrongly labelled" and "correctly labelled but void" is worth recording, because the remedy differs.

Conclusion. Breadth 3 independent sources, claim count 4 independent claims, net conviction mixed and tilted negative. The Synthos knowledge base's independent view of Regeneron is dominated by the 2031 Dupixent patent cliff, a manufacturing complete-response letter, and a named oral competitor to its largest product — against neutral-to-positive notes on muscle biology and gene therapy. The ten management claims are excluded from the score and are the most useful factual content in the lane. The four competitor claims are excluded as stale.

5. Technicals

• Price $760.49, +0.16%. 6.4% below the 52-week high of $812.27; 39.3% above the low of $545.94. Position within the annual range: 81st percentile.
• +17.3% above the 50-day of $648.23 — the widest gap to a fifty-day average in this batch — and +6.9% above the 200-day of $711.59.
• RSI 79.2 — the highest reading in this batch. MACD +26.70, also the highest.
• max_dd_from_peak reads −36.70% against pct_from_hi of −6.35%. On this name the two DIFFER, so the field genuinely records a trailing-year maximum drawdown — and it was severe. The stock fell 36.7% from peak to trough within the last twelve months and has recovered almost all of it. This confirms the field's definition is inconsistent across files in this batch: on four of the seven names examined it equals pct_from_hi exactly, and here and on one other it does not.
• Relative performance: 3-month +7.3% against SPY +7.6%; 6-month +0.7% against +11.1%; 12-month +36.1% against SPY +24.3% and QQQ +30.8%. Almost all of the twelve-month outperformance was generated in the last three months, off a 36.7% drawdown.
• Sentiment: 34 buy, 15 hold, 0 sell across 49 analysts; consensus target $819.59 (+7.8%), median $800, high $1,030 (+35.4%), low $641 (−15.7%). No sell rating on a company whose 2027 earnings estimates span 115%.

6. Data integrity — a single-cause 10⁶ units error, and everything it destroys

Six findings. Regeneron's km_ttm and ratios_ttm blocks contain the most visibly absurd numbers in this programme, and they have one cause.

1. Every balance-sheet-derived ratio is wrong by a factor of 1,000,000 — DIAGNOSED and REPAIRABLE. The balance-sheet inputs to km_ttm and ratios_ttm are stored in millions while the price and income inputs are in units. Every ratio that divides by a balance-sheet quantity is inflated by 10⁶; every ratio that divides INTO one is deflated by the same factor. The repair is exact and the repaired figures are sensible:

Every one of these is REJECTED as printed and REPAIRED as shown; the dive uses the repaired figures and says so at each use. The unaffected ratios — priceToEarningsRatioTTM (18.16x), priceToSalesRatioTTM (5.04x), grossProfitMarginTTM (84.86%), netProfitMarginTTM (27.86%), revenuePerShareTTM ($150.24), netIncomePerShareTTM ($41.86), freeCashFlowPerShareTTM ($34.06) and effectiveTaxRateTTM (16.21%) — are all income-statement or price derived and all appear correct. The diagnostic value here is that the error is perfectly separable: income-statement ratios clean, balance-sheet ratios uniformly wrong by 10⁶.

2. capitalExpenditure and investmentsInPropertyPlantAndEquipment DIVERGE in fiscal 2025 — a definition change — REJECTED as a free-cash-flow input. For FY2025 the payload reports investmentsInPropertyPlantAndEquipment of −$1,213.7M and capitalExpenditure of −$898.4M — a $315.3 million difference within the same file. For FY2024 both read −$755.9M, identical. freeCashFlow of $4,080.5M is computed on the SMALLER figure ($4,978.9M − $898.4M); on the larger one it is $3,765.2M, 7.7% lower. The 10-Q's first-half capital expenditure of $470.8M (against $448.3M) annualises near $950M and is disclosed separately from "payments for intangible assets" of $99.9M, which suggests the $315.3M divergence is the intangible line being included in one field and not the other. We use operating cash flow less filed capital expenditure and quote no vendor free-cash-flow figure. capexToDepreciationTTM of 1.742 is not reliable while the numerator's definition is ambiguous.

3. netDebt omits $5,487.1 million of short-term investments — REJECTED. The payload's netDebt of −$412.2M is totalDebt ($2,705.9M) less cash ($3,118.1M) only. Adding short-term investments of $5,487.1M and removing the $720M of capitalLeaseObligations from the debt figure gives net cash of approximately $6,619M — 8.4% of market capitalisation, sixteen times the payload's figure. This is the documented short-term-investment omission, and on this name it is material to every enterprise-value calculation.

4. capitalLeaseObligations of $720.0M is IDENTICAL in fiscal 2025 and fiscal 2024 — REJECTED as a debt component. The same figure to the hundred thousand in two consecutive years, added on top of longTermDebt of $1,985.9M and $1,984.4M (themselves within $1.5M of each other). A lease obligation that does not amortise by a single dollar across a year is not a lease obligation; it is a carried-forward constant. Excluded from the debt calculation.

5. est.ebitdaAvg and est.ebitAvg carry the fixed-ratio fabrication signature — REJECTED. In all eight years from 2023 to 2030, ebitdaAvg is exactly 43.4322% of revenueAvg and ebitAvg exactly 40.4351%. The implied 40.4% EBIT margin is roughly fifteen points above Regeneron's actual operating margin of 25.6%. All forward valuation uses epsAvg only.

6. seg_prod and seg_geo were examined and are not used. The 10-Q's own revenue table — which splits EYLEA HD, EYLEA, Libtayo, Praluent, Evkeeza, Lynozyfic and each collaboration partner, for both periods, with dollar changes — is strictly better than anything in the payload, and it is the source of every revenue figure in this dive. No defect is alleged; the blocks are superseded.

Verified clean — recorded:

• inc_q for the June 2026 quarter reconciles to the filing on revenue ($4,290.7M) and net income ($1,296.9M); epsDiluted of $12.20 against a filed $12.23 is a 0.2% rounding difference.
• bal_a FY2025 is correct throughout — cash $3,118.1M, short-term investments $5,487.1M, total assets $40,558.7M, total equity $31,256.9M, and goodwill of ZERO, which is correct: Regeneron carries none.
• minorityInterest is 0 and correctly so. The NCI-omission class was checked and does not apply.
• All income-statement-derived ratios are clean (finding 1), including grossProfitMarginTTM of 84.86%, which reconciles to the filed gross profit of $12,242.2M on revenue of $14,342.9M for fiscal 2025.
• researchAndDevelopementToRevenueTTM of 41.59% reconciles to filed R&D of $5,850.2M on revenue of $14,342.9M — 41.8%. This is one of the few names in this batch where that field is populated and correct.

Peer set — REJECTED as mostly irrelevant. The vendor peers are Alnylam, argenx, Cigna, Cencora, Elevance Health, Genmab, IDEXX Laboratories, Incyte, United Therapeutics and Zoetis. Three are health insurers or distributors (Cigna, Cencora, Elevance) with no product economics in common; one is a veterinary diagnostics company; one is an animal-health company. Amgen, Vertex, Biogen and Gilead — the obvious large-cap biotechnology comparables — are all absent. No peer-multiple comparison is drawn.

Vendor composite rating — noted, and its price-to-book sub-score rejected outright. rating gives A / 4 overall with 1 on price-to-book. That sub-score is computed on a price-to-book ratio of 2,479,728x. The repaired figure is 2.48x, which would score well. The rating block is scoring a units error.

Non-equity tripwire — checked and passed. REGN is Common Stock, par value $0.001, NASDAQ Global Select Market, per the 8-K cover page. Beta 0.236; volume 739 thousand shares (~$562M of turnover); the 52-week band of $545.94 to $812.27 is a 49% range. This is common equity.

7. Insiders — one transaction, 200 shares

The entire insider file contains one transaction: a director's sale of 200 shares at $650.15 on 2026-07-02 — approximately $130,000, and 1.1% of a 17,503-share position. The sale price is 14.5% below today's close.

There is no executive-officer transaction of any kind in the window, no option exercise, no tax withholding and no purchase. On a founder-led company where Leonard Schleifer and George Yancopoulos hold significant stakes, the complete absence of any activity by either is uninformative rather than encouraging. Two hundred shares is not evidence.

8. Verdict, kill-criteria and flip conditions

Hold.

What is genuinely excellent here. Regeneron is one of a very small number of companies that has repeatedly invented approvable medicines from its own platform. It carries zero goodwill, an 84.9% gross margin, approximately $6.6 billion of net cash, and spends 41.6% of revenue on research and development — all of it expensed, which understates the economics of a working discovery engine. It returned $4,341 million to shareholders in fiscal 2025, 5.54% of market capitalisation, and has a new $3.0 billion authorisation with no time limit. It has a dated pipeline calendar — garetosmab under FDA priority review with a target action date THIS MONTH, cemdisiran in the fourth quarter, fianlimab in melanoma, Factor XI entering Phase 3 — and, per management, an agreement with the US government exempting it from future pricing mandates. At 13.0x the 2027 consensus, or 11.9x excluding net cash, that is not an expensive price.

Why the verdict is nonetheless Hold, in three facts from the filing.

First, the growth is one line. Sanofi collaboration revenue rose $730.7 million; total revenue rose $615.1 million. Total net product sales — everything Regeneron owns outright — rose 0.7%. US EYLEA fell 45.4%. The combined ophthalmology franchise fell 12.1% and the company says the magnitude and duration of biosimilar impact "is presently unknown."

Second, GAAP earnings fell. Net income $1,296.9 million against $1,391.6 million, MINUS 6.8%; diluted EPS $12.23 against $12.81, MINUS 4.5% — on revenue up 16.7%. Operating cash flow in the first half fell 13.6% while revenue rose 17.8%. The 40.6% adjusted beat and the GAAP decline are both true, and only one of them is being discussed.

Third, nobody knows what this earns. The 2027 consensus EPS range is $32.09 to $69.15 — a 115% spread on ten analysts, more than three times anything else in this batch — and the reason is legible: an eroding legacy franchise, a partnered growth franchise with a 2031 expiry the knowledge base sizes at roughly $25 billion, and a pipeline of binary outcomes. A base fair value struck on the mean of that distribution carries very little information, and ours is $790, 3.9% above spot, at 1.19:1 asymmetry.

And the entry is poor. RSI 79.2 — the highest in this batch — 17.3% above the fifty-day average, after a 36.7% peak-to-trough drawdown inside the last twelve months that has been almost entirely recovered in three months.

Pre-registered UPGRADE conditions — what would take this to Watch or Buy — Tactical:

• Total net product sales returning to growth above 5%, from 0.7% — this is the primary trigger, because it is the only evidence that the business works without the Sanofi line.
• US EYLEA stabilising above $400 million a quarter, ending the 45.4% decline.
• Garetosmab approval in August 2026, followed by cemdisiran in the fourth quarter — two approvals inside six months would begin to answer the replacement question.
• A price below approximately $645, which is 11x the FY2027 consensus mean and 10x ex-cash, and would restore asymmetry near 2:1 without any change to the estimates.
• The FY2027 estimate range narrowing below 50%, which would mean the market had resolved something.

Pre-registered KILL criteria — what would take this to Avoid:

• US EYLEA falling below $350 million a quarter, or the combined ophthalmology franchise declining more than 20%.
• Sanofi collaboration revenue growth falling below 20%, removing the only growth engine.
• A further complete response letter or manufacturing interruption, after the Limerick episode and the complete-response letter an independent source recorded.
• Positive Phase 2 data for an oral Dupixent competitor — the knowledge base names a specific candidate at conviction 65.
• Any dilution or reversal of the government pricing agreement management describes.
• The buyback slowing materially below the $4 billion annual pace, which supplies 5.5 points of the expected return and exceeded free cash flow by 52% in the first half.

Where REGN fits in the Synthos Framework Portfolio. Not entered today. Held on the watch list with a trigger price of ~$645 and an event trigger of total net product sales returning to growth. Sizing note: this is a high-quality science business whose outcome distribution is genuinely wide, and the correct response to a 115% estimate range at an RSI of 79 is to wait for either a lower price or a narrower distribution — both of which are observable. Logged as a tracked Synthos call (Hold) as of 2026-08-04 at $760.49, with the fair-value anchors, kill criteria and upgrade conditions all gradeable.

Single biggest risk: concentration, on both ends of the barbell. 50.7% of June-quarter revenue was a single partnered product line whose patent expires around 2031 and which an independent knowledge-base claim sizes at roughly $25 billion of sales. Meanwhile the franchise Regeneron owns outright and built itself — EYLEA — fell 45.4% in the United States in one quarter as biosimilars arrived, and the replacement product recovered only 59% of the loss. A company whose growth comes entirely from a partner's product and whose own product is being eroded by generics is running two clocks at once, and neither is under its control. What it does control is the pipeline, at 41.6% of revenue and roughly fifty candidates — and the honest statement is that nothing currently disclosed is sized to replace Dupixent. The 115% dispersion in the 2027 consensus is not analyst confusion; it is the correct measure of that uncertainty, and no fair value struck on its mean deserves more confidence than the distribution allows.

Provenance & disclosures

• Traceability: 26 raw hits, 24 exact case-sensitive entity matches, and only 4 independent name-level claims survive (breadth 3 independent sources; net conviction mixed and tilted negative). The independent lane is biotech_hangout: 2025-09-11 (bearish, conviction 65) — "Sanofi's amlitelimab hit its endpoint but trails Dupixent on efficacy; won't offset Dupixent's ~$25B 2031 patent loss, raising a new bear case" — the central bear case for this company; 2025-10-31 (bearish, conviction 70) recording that "Scholar Rock and Regeneron received CRLs — a broad manufacturing headwind", which corroborates the company's own Limerick disclosure; and two neutral factual claims on muscle biology and the DB-OTO gene therapy. A text-only claim at conviction 65 identifies Kymera's oral STAT6 degrader as a "potential oral Dupixent competitor" with 90% degradation in healthy volunteers — a specific competitive threat to the line supplying 50.7% of revenue. TEN of the twenty-four entity matches are REGN_mgmt at skill 0.5, all dated 2026-04-29 from a single earnings communication: EXCLUDED from the conviction pool per house rule and quoted at half weight, their factual content (a new $3.0bn repurchase authorisation, a $0.94 dividend, a US government agreement exempting the company from future pricing mandates with three years of tariff relief in exchange for most-favoured-nation pricing, a garetosmab priority review with a target action date in August 2026, a cemdisiran decision in Q4 2026, fianlimab readouts, Factor XI Phase 3 initiations, and the Limerick gross-margin drag) being the most useful forward calendar available and appearing nowhere in the payload. FOUR claims arrive on the eli_lilly_ceo channel carrying Regeneron in their entity lists — the documented cross-contamination class this dive was directed to check. On inspection they are NOT misattributed: they are genuine comparative statements about Regeneron's COVID-19 antibody cocktail made by a competitor's chief executive between 2020-09-04 and 2021-06-19, correctly tagged, about a product line that no longer contributes materially. They are excluded as STALE COMPETITOR COMMENTARY rather than as mislabelled, and the distinction is recorded because the remedy differs. All quotes are verbatim from the stored claim text.
• Data as-of: revenue by product and collaboration partner, income statement, cash flow and the Sanofi collaboration terms through 2026-06-30, all filing-verified from the 10-Q filed 2026-07-30; annual balance sheet and cash flow for fiscal 2025 and 2024 from the payload, cross-checked against the 10-K filed 2026-02-04 · estimates 2026-08-04 · prices 2026-08-04, quote timestamp 1785873600 = 2026-08-04T20:00:00Z ($760.49, +0.16%; 50-DMA $648.23; 200-DMA $711.59; RSI 79.2; MACD +26.70) · knowledge-base claims 2026-08-04. Regeneron's fiscal year is the calendar year. All figures come from the Synthos vendor data file for REGN or from the SEC filings in the REGN archive; no figure comes from memory, recall or external retrieval.
• Filing archive contents: 10-K filed 2026-02-04 (fiscal 2025); 10-Q filed 2026-04-29 (March 2026 quarter); 10-Q filed 2026-07-30 (June 2026 quarter — the source of the revenue decomposition, the cash flow and the Sanofi collaboration terms); 8-K filed 2026-06-17 (Item 5.07, annual meeting results); 8-K filed 2026-07-06 (Item 2.02); 8-K filed 2026-07-30 (Item 2.02, second-quarter results — the press release is Exhibit 99.1 and was NOT extracted, so no management guidance or non-GAAP reconciliation is available to this dive). All three 8-Ks were read. There is NO corporate action in this archive — no acquisition, divestiture, financing or restructuring. All filings carry preserved [TABLE] statement data.
• Where the filings contradicted or corrected the vendor (detailed in Section 6): a single-cause 10⁶ UNITS ERROR in every balance-sheet-derived ratio in km_ttm and ratios_ttm, producing priceToBookRatioTTM of 2,479,728.36 (repaired: 2.48x), bookValuePerShareTTM of $0.0003067 (repaired: $306.68), returnOnAssetsTTM of 103,731 (repaired: 10.37%), returnOnInvestedCapitalTTM of 91,897 (repaired: 9.19%), assetTurnoverTTM of 372,267 (repaired: 0.372x), inventoryTurnoverTTM of 762,604, solvencyRatioTTM of 484,809, cashPerShareTTM of $0.0000773 (repaired: $77.32), workingCapitalTTM of 12,915.4 (i.e. $12,915.4 million), enterpriseValueTTM of $78,347,200,310.8 — market capitalisation less $469 — and netDebtToEBITDATTM of −8.33 × 10⁻⁸ (repaired: −0.083x) — all REJECTED as printed, all REPAIRED by the stated factor, and the repaired values all reconcile to the filings; capitalExpenditure of −$898.4M DIVERGING from investmentsInPropertyPlantAndEquipment of −$1,213.7M in fiscal 2025 — a $315.3M within-file inconsistency, with freeCashFlow computed on the smaller figure, against fiscal 2024 in which both read −$755.9M identically; netDebt of −$412.2M, which omits $5,487.1 million of short-term investments and includes $720M of lease obligations in debt, understating the true net-cash position of approximately $6,619M by a factor of sixteen; capitalLeaseObligations of $720.0M IDENTICAL in fiscal 2025 and fiscal 2024, a lease that amortised by nothing across a year; and est.ebitdaAvg/ebitAvg, at exactly 43.4322% and 40.4351% of revenueAvg in all eight years from 2023 to 2030, implying an EBIT margin roughly fifteen points above the company's actual 25.6%. Where vendor and filing AGREED — recorded: every income-statement-derived and price-derived ratio is clean, including priceToEarningsRatioTTM (18.16x), priceToSalesRatioTTM (5.04x), grossProfitMarginTTM (84.86%, reconciling to filed gross profit of $12,242.2M on revenue of $14,342.9M), netProfitMarginTTM (27.86%), revenuePerShareTTM ($150.24), netIncomePerShareTTM ($41.86), effectiveTaxRateTTM (16.21%) and researchAndDevelopementToRevenueTTM of 41.59% against a filed 41.8% — one of very few names in this batch where that field is both populated and correct; inc_q June-2026 revenue of $4,290.7M and net income of $1,296.9M reconcile exactly to the 10-Q, with epsDiluted of $12.20 against a filed $12.23, a 0.2% rounding difference; bal_a FY2025 is correct throughout, including goodwill of ZERO, which is right — Regeneron carries none; and minorityInterest of 0, correct, with the NCI-omission class checked and inapplicable. The separability of the units error is itself the diagnostic finding: income-statement ratios clean, balance-sheet ratios uniformly wrong by exactly 10⁶.
• Estimate coverage, and it is the weakest link in this dive: 16 analysts on FY2026 EPS with a 35% range ($45.98 to $62.07); only 10 on FY2027 EPS — the anchor for all three fair values — with a range of $32.09 to $69.15, a 115% SPREAD, more than three times the widest dispersion elsewhere in this batch; and 8 on FY2028 with a 28% range. 19 analysts carry a FY2027 revenue estimate against 10 carrying an EPS estimate, which is the standard signature of a genuinely unknown cost or margin path. The FY2027 low of $32.09 is treated as an outlier and is NOT used as a bear anchor; the bear case is struck at 9.55x the mean instead, and the reasoning is stated in Section 3. est.ebitdaAvg and est.ebitAvg are rejected outright and all forward valuation uses epsAvg only.
• Peer note: the vendor peer set — Alnylam, argenx, Cigna, Cencora, Elevance Health, Genmab, IDEXX Laboratories, Incyte, United Therapeutics, Zoetis — contains three health insurers or distributors, a veterinary diagnostics company and an animal-health company, and omits Amgen, Vertex, Biogen and Gilead entirely. No peer-multiple comparison is drawn.
• Fair-value caveat: the $560 / $790 / $1,000 anchors are struck on the FY2027 consensus adjusted EPS distribution — 9.55x and 13.5x the mean of $58.63671 and 14.5x the high of $69.15289 — cross-checked against the FY2026 row and against net cash of approximately $6.6 billion (8.4% of market capitalisation, giving ex-cash multiples of 13.2x, 11.9x and 10.6x on the three forward years). Stated arithmetic, not a discounted cash flow. The base is sensitivity-disclosed: 11x gives $645, 13.0x gives $761 — spot to fifty cents — and 17x gives $997. The base assumes a modest multiple expansion driven not by a re-rating of biotechnology but by the compression of a 115% estimate range as the EYLEA transition resolves; at an unchanged multiple the twelve-month return is 11.4% of earnings growth plus 5.54% of shareholder yield, roughly 17%. Every anchor here carries less confidence than elsewhere in this batch, for the coverage reason stated above, and that is the principal reason the verdict is Hold.
• Basis note: analyst estimates and the earn_cal actuals are on adjusted earnings, which run materially ABOVE GAAP in this file — June-quarter adjusted $14.29 against GAAP $12.23, and the pattern holds in prior quarters. The reconciliation is not available because the earnings release (Exhibit 99.1 to the 2026-07-30 8-K) was not extracted. All forward multiples use the adjusted consensus; the GAAP decline of 6.8% in net income and 4.5% in diluted EPS is reported separately and is not netted against the adjusted beat.
• Guidance note: the earnings releases carrying management's outlook are Exhibits 99.1 to the 2026-04-29, 2026-07-06 and 2026-07-30 8-Ks and were not extracted, so no management financial guidance is available to this dive. The forward statements used — the pipeline calendar, the repurchase authorisation, the government pricing agreement and the Limerick gross-margin drag — come from the ten REGN_mgmt knowledge-base claims dated 2026-04-29, are management voice at skill 0.5, are excluded from the conviction pool, and are quoted at HALF WEIGHT per house rule. Earnings-call transcripts are not available on the current data plan.
• Timing: second-quarter 2026 results were released 2026-07-30, five days before this dive, and beat consensus adjusted EPS by 40.6% ($14.29 against $10.16) on revenue of $4,290.7M against $3,817.3M estimated. A nearer catalyst than the next print exists and is unusual: management has disclosed a garetosmab BLA under FDA priority review with a target action date in AUGUST 2026 — within this month. The next print is 2026-10-28, 85 days away. The only insider filing is dated 2026-07-02 and is a director's sale of 200 shares. 2026-08-04 carried no company-specific filing.
• Accessibility note: no information in this dive is conveyed by colour. All emphasis is carried by bold text, table structure and explicit labelling.
• Not investment advice. Independent research, educational and informational only, never personalised. No recommendation to buy, sell or hold any security is made to any person.
• Version: 2026-08-04-full.